Candesartan

DB13919InvestigationalSmall moleculeAngiotensin 2 Receptor Blocker

Candesartan is an angiotensin-receptor blocker indicated in the treatment of hypertension. It is available as a prodrug in the form of candesartan cilexetil.

Chemical structure of Candesartan
Mechanism
Curator reviewed
Formula / weight
C24H20N6O3 · 440.454 g/mol (avg)
Code names
CV-11974

Resolves to

Compound
UNIIS8Q36MD2XXCAS139481-59-7ChEMBLCHEMBL1016ChEBI3347PubChem2541KEGGD00522
Clinical / RWD
RxNorm214354ATCC09CA06ATCC09DA06ATCC09DB07PharmGKBPA448765
Structure
InChIKeyHTQMVQVXFRQIKW-UHFFFAOYSA-NSMILESCCOC1=NC2=CC=CC(C(O)=O)=C2N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1
Targets
P30556AGTR1
Transporters
P08183ABCB1Q9Y6L6SLCO1B1

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2TransportersSubstrate / inhibitor direction, not just membership
Listed above
1,081Drug interactionsStructured to mechanism, not free text
Sign in
79Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1,747Marketed productsAcross 7 countries and 38 labellers
Sign in
5ATC codesIncluding every combination product, plus 25 drug categories
Sign in
29+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Candesartan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In